Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dyslipidaemias Clear all
Terminated No phase listed Observational Accepts healthy volunteers

Effect Of GW501516X On How The Heart Obtains And Uses Energy

NCT00318617
View directory record Official record
Conditions
Dyslipidaemias, Heart Failure
Interventions
GW510516X
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 20, 2026, 2:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation

NCT00388180
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidaemias, Obesity
Interventions
GW501516, GW590735
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 20, 2026, 2:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of Pharmacokinetics and Pharmacodynamics Effects Of GSK256073A On Healthy Volunteers

NCT00488449
View directory record Official record
Conditions
Healthy Subjects, Dyslipidaemias
Interventions
GSK256073A tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 20, 2026, 2:28 PM EDT
Completed Phase 2 Interventional

Dyslipidemia Study Investigating The Increase In "Good Cholesterol"

NCT00169559
View directory record Official record
Conditions
Dyslipidaemias
Interventions
GW590735, fenofibrate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2012 · Synced Oct 20, 2026, 2:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Repeat Dose Food Effect Study of GSK256073F in Healthy Adult Subjects

NCT00808093
View directory record Official record
Conditions
Dyslipidaemias
Interventions
GSK256073
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 20, 2026, 2:28 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

NCT01218204
View directory record Official record
Conditions
Dyslipidaemias, Dyslipidemias
Interventions
10mg atorvastatin, 80mg atorvastatin, GSK1292263 Placebo, 100mg GSK1292263, 300mg GSK1292263, 800mg GSK1292263, 10mg ezetimibe, Washout
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
21
States / cities
Anniston, Alabama • Chula Vista, California • Stockton, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 20, 2026, 2:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers

NCT00608699
View directory record Official record
Conditions
Healthy Subjects, Dyslipidaemias
Interventions
GSK256073A tablets + IR niacin tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Oct 20, 2026, 2:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.

NCT00783549
View directory record Official record
Conditions
Dyslipidaemias
Interventions
an undetermined dose of GSK1292263, ascending dose of GSK1292263
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Oct 20, 2026, 2:28 PM EDT
Completed Phase 2 Interventional Results available

Study to Test GSK256073 in Patients With Dyslipidemia

NCT00903617
View directory record Official record
Conditions
Dyslipidaemias, Dyslipidemias
Interventions
GSK256073, Placebo, Niaspan
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Pembroke Pines, Florida • Indianapolis, Indiana • Louisville, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Oct 20, 2026, 2:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Second Study to Determine the Effect of GSK256073A on HVTs

NCT00551694
View directory record Official record
Conditions
Healthy Subjects, Dyslipidaemias
Interventions
GSK256073A tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 20, 2026, 2:28 PM EDT